First Trust Advisors LP Recursion Pharmaceuticals, Inc. Transaction History

First Trust Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$7.35 - $10.05 $2.08 Million - $2.84 Million	-282,871 Reduced 74.89%	94,854 $711,000
Q1 2024 May 13, 2024	BUY	$9.13 - $15.52 $1.14 Million - $1.94 Million	125,032 Added 49.48%	377,725 $3.77 Million
Q4 2023 Feb 13, 2024	BUY	$5.09 - $10.79 $92,999 - $197,144	18,271 Added 7.79%	252,693 $2.49 Million
Q3 2023 Nov 13, 2023	BUY	$6.59 - $15.86 $1.24 Million - $2.99 Million	188,685 Added 412.54%	234,422 $1.79 Million
Q2 2023 Aug 14, 2023	BUY	$4.56 - $9.94 $208,560 - $454,625	45,737 New	45,737 $341,000
Q4 2022 Feb 09, 2023	BUY	$7.16 - $12.7 $799,836 - $1.42 Million	111,709 Added 86.3%	241,147 $1.86 Million
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $1.01 Million - $1.76 Million	129,438 New	129,438 $1.38 Million

286

242M

1.35M

2.32M

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.12B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.